1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N-[(3S)-1-pyrrolo[1,2-a]pyrazin-1-yl-3-pyrrolidinyl]- manufacturers
|
| | 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N-[(3S)-1-pyrrolo[1,2-a]pyrazin-1-yl-3-pyrrolidinyl]- Basic information |
| | 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N-[(3S)-1-pyrrolo[1,2-a]pyrazin-1-yl-3-pyrrolidinyl]- Chemical Properties |
| density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 9.52±0.20(Predicted) | | color | Off-white to gray |
| | 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N-[(3S)-1-pyrrolo[1,2-a]pyrazin-1-yl-3-pyrrolidinyl]- Usage And Synthesis |
| Uses | 1-(4-Fluorophenyl)-N-[(3S)-1-pyrrolo[1,2-a]pyrazin-1-yl-3-pyrrolidinyl]-1H-pyrazole-3-carboxamide is a useful intermediate for the preparation of other bioactive compounds with biological properties. | | in vivo | CXCR7 antagonist-1 (10 μM, intranasal instillation, once a day, 2 doses) inhibits the airway smooth muscle relaxation induced by RSV-infection in BALB/c mouse models[2]. | Animal Model: | RSV-infected BALB/c mouse models[2] | | Dosage: | 10 μM | | Administration: | intranasal instillation, once a day on days 7 and 8 after RSV infection. | | Result: | Improved the impaired airway relaxation response to β2AR agonists, restored the airway relaxation function. |
| | IC 50 | CXCR7 |
| | 1H-Pyrazole-3-carboxamide, 1-(4-fluorophenyl)-N-[(3S)-1-pyrrolo[1,2-a]pyrazin-1-yl-3-pyrrolidinyl]- Preparation Products And Raw materials |
|